Australia's overdose report 2026: stimulants at record, over-50s hardest hit

There is a cohort in Australia that nobody built the system for.

They started using drugs in the 1980s. Some were teenagers. Some were at university. Some were prescribed opioids for a back injury that never quite resolved, or took stimulants to manage the grind of middle age, or kept using substances they had used recreationally for decades without the health system noticing them closely. They are now in their fifties.

For the first time, people aged 50 to 59 are the single largest cohort of unintentional drug deaths in Australia. In 2024, they accounted for 533 deaths — 25.5% of total unintentional overdoses, more than any other age group, more than the 40-49 cohort that had previously held that position. Deaths in the 50-59 group have increased more than fivefold since 2001. Deaths in the 60-69 group have tripled.

The Penington Institute’s Australia’s Annual Overdose Report 2026, released this week and drawing on 2024 mortality data, records 2,596 drug-induced deaths in total — 2,091 of them classified as unintentional. That 2,091 figure is a record. Since 2001, Australia’s population grew 41%. Over the same period, unintentional drug-induced deaths grew 113%.

The maths does not ask you to interpret it kindly.

---

The stimulant story inside the numbers

The most striking single-year movement is in stimulants. Stimulant-related deaths rose 25% in 2024 to 772 — also a record high. That is 36.9% of all unintentional overdose deaths, compared to opioids at 41.9%. The gap between the two has narrowed sharply.

Heroin deaths are also at a record: 488 in 2024, up from 101 in 2001. The image of heroin as a 1980s-90s phenomenon does not match the data. Pharmaceutical opioids account for 42.2% of opioid deaths — a figure that implicates the prescribing environment as much as the illicit supply chain. And 67.8% of deaths involved multiple substances. Almost nobody in this data died from one thing in isolation.

Western Australia records the highest rate at 9 per 100,000, up 233% since 2004. Rural areas record 8.1 per 100,000, compared to 7.1 in metropolitan regions. The geography of risk is not evenly distributed.

---

Both sides of this

The uncomfortable both-and here is that the harm-reduction architecture in Australia was designed around a younger profile of drug use. Needle and syringe programmes, naloxone take-home schemes, drug checking services — these are valuable and necessary. But they were conceived when the overdose death profile looked different.

The 50-year-old woman who is on chronic opioid therapy for a musculoskeletal condition, who also takes benzodiazepines for sleep, who also occasionally uses cannabis — that patient exists in GPs’ rooms across Australia every week. The 55-year-old man who has been using methamphetamine intermittently for twenty years and whose cardiac function has been quietly deteriorating — he may not identify as a “drug user” in the way harm-reduction messaging has historically framed it.

This is not a reason to despair. It is a reason to update the mental model.

The Penington Institute’s call for adapted harm-reduction strategies targeting middle-aged and older populations is not radical. It is descriptive. The population of people who use drugs is ageing. The population of people who die from drug use is now majority over-50. The clinical response has not fully caught up.

---

What this means this week

A few things worth carrying into general practice from this data.

First: naloxone access has expanded in Australia — it is available without prescription from most pharmacies. If there are people in your orbit who use opioids — prescribed or otherwise — knowing it exists, and that it is free to access, is the kind of information that saves lives. NPS MedicineWise has accessible guidance on naloxone.

Second: polypharmacy in the over-50s is the quiet risk factor here. Prescribed opioids combined with benzodiazepines, antihistamines, or alcohol depresses respiratory drive in ways that a younger person might weather and an older person may not. It is worth asking — gently, and without judgment — about what else is in the mix.

Third: the stimulant data is not separate from the GP workup. Methamphetamine use accelerates cardiovascular disease. A 52-year-old presenting with chest pain or palpitations is not automatically a cardiac presentation — it may be a substance-related presentation in a person who has never disclosed use because nobody asked in a way that felt safe.

---

Verdict: yes — worth knowing about.

The death toll is a number. What it is counting is people in their fifties, dying at a rate the system was not designed to prevent. That is a design problem. It can be redesigned.

---

Sources cited

1. Overdose deaths shift older as stimulant toll hits record high — Medical Republic (Sep 2026)
2. Penington Institute — Australia’s Annual Overdose Report 2026
3. NPS MedicineWise — naloxone information for consumers